ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 0994

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 1143

Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1278

Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 0886

Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation

(0886–0898) SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1261

Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients

(1256–1263) Psychology/Social Science – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 0918

Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0971

Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1541

Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1251

Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1454

Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1339

Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 0913

Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0902

Neutrophils in Systemic Lupus Erythematosus Demonstrate Heterogeneity Based on Sex

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0948

Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1071

No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

(1052–1081) Immunological Complications of Medical Therapy Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].